Author Archives

Recent Author Comments

On Angel's "World's First Trillionaires Will Come From THIS" pitch, detangled
This is the worst spot of all to print a teaser like this. It made me laugh, though, so I appreciate it.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
$THANKS to ALL May you always have Love to Share, Cash to Spare, And Friends who Care.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
$Happy Thanksgiving By now the stuffed turkey is probably in the oven, spreading a tempting aroma throughout the house. I hope you are all surrounded by family and friends that love and support you. I am so grateful for the amazing people in this unusual [...]
On Microblog: Halo-Fi
Greg Wyler is the CEO behind OneWeb and O3B Networks (Halo-fi.) They operate out of Arlington, VA. The IPO is Dec 8th.[...]
On Microblog: Ethereum: The Battle Of The Chains... Kraken-ETC ETH & more...
Does anybody have the bitcoin/blockchain tickers? $RIOT $GBTC what else?[...]
On Microblog: Ethereum: The Battle Of The Chains... Kraken-ETC ETH & more...
cannot understand how all this code written in javascript(that is what I heard) will scale up?[...]
On 2017 Turkey of the Year
NVDA. I also dropped as it went down to $100. In a few months it's gone to $215. Luckily I got in at $30. Still kicking myself. Happy Thanksgiving everyone.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
If I had to guess, I'd say what's going on here is that they are SO justifiably psyched by their new pre-clinical cell culture model Alzheimer data that they've decided to kick that program into a higher gear. Which makes total sense and will thrust the co[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
$ONCS - long When Dr. KSS first brought it to our attention, I bought a bit of ONCS. Since then, I've been reading up on the company. This resulted in further buys, as I increasingly felt more secure about the science. (I never feel safe in a clinical-[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
There is a good point embedded in this, which is that the heart essentially never gets involved with cancer, at least not in the myocardium. And there must be a reason for that. The commonest heart neoplasm is atrial myxoma, and it is rare and non-malignan[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
This forum could NEVER be what it is without you Glenn....I cherish you and your friendship. Happy Thanksgiving! Hope your kids are with you this holiday.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
My reply to this would be that while we know exosome trafficking exists, and that it represents a route for lots of reciprocating one-way communications between cells, we don't know whether its epiphenomenology or whether it's clinically relevant. Exosomes[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
$CAPR, The comment contained a ticker symbol. In any case, the paper's title is: Harnessing the heart’s resistance to malignant tumors: cardiac-derived extracellular vesicles decrease fibrosarcoma growth and leukemia-related mortality in rodents. Aut[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
$CWBR -Long. Happy Thanksgiving one and all. I am very excited by CWBR 100Million shelf offering. It should give them much better leverage in negotiating terms of future JV's.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
They are having a meeting to discontinue a Board member. Irrational price action in my mind. Probably guilty of sexual assault but just guessing due to current corporate climate.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Comment Link: https://www.stockgumshoe.com/reviews/global-trend-trader/2017-turkey-of-the-year/comment-page-1/#comment-4961197 Author: admdr5 Comment: $ PIRS LONG 23-Nov-2017:07:48:00, Pieris Pharmaceuticals Appoints James Geraghty as Chairman [...]
On 2017 Turkey of the Year
$ PIRS LONG 23-Nov-2017:07:48:00, Pieris Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors BOSTON, MA - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics [...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Opens the door for the cancer assassinating agent.[...]
On 2017 Turkey of the Year
Careful. A close friend works for them and describes a dysfunctional corporate climate.[...]
On Microblog: Fintech startup ICONOMI raised $5 million in ongoing digital IPO (open to public).
The #Iconomi Burn — Crypto Buybacks https://hackernoon.com/the-iconomi-burn-crypto-buybacks-f9edb30530fe[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.